| 1 |
Hayashi N. Rapid screening methods for universal binding peptide aptamers against SARS-CoV-2 variant spikes, including omicron variants, and their application to diagnostic and therapeutic agents.. [DOI: 10.21203/rs.3.rs-2609957/v1] [Reference Citation Analysis]
|
| 2 |
Dhama K, Nainu F, Frediansyah A, Yatoo MI, Mohapatra RK, Chakraborty S, Zhou H, Islam MR, Mamada SS, Kusuma HI, Rabaan AA, Alhumaid S, Mutair AA, Iqhrammullah M, Al-Tawfiq JA, Mohaini MA, Alsalman AJ, Tuli HS, Chakraborty C, Harapan H. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health 2023;16:4-14. [PMID: 36446204 DOI: 10.1016/j.jiph.2022.11.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 3 |
Yaqun Fu, Jingyu Zhao, Xia Wei, Peien Han, Li Yang, Tao Ren, Siyan Zhan, Liming Li. Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China. Vaccines (Basel) 2022;10:1712. [PMID: 36298577 DOI: 10.3390/vaccines10101712] [Reference Citation Analysis]
|
| 4 |
Giron CC, Laaksonen A, Barroso da Silva FL. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. Journal of Biomolecular Structure and Dynamics. [DOI: 10.1080/07391102.2022.2095305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Lee ARYB, Wong SY, Tay SH. Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety. Vaccines 2022;10:668. [DOI: 10.3390/vaccines10050668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 6 |
Deng W, Lv Q, Li F, Liu J, Song Z, Qi F, Wei Q, Yu P, Liu M, Zhou S, Zhang Y, Gao H, Wang N, Jia Z, Gao K, Liu J, Xiao C, Shang H, Wang X, Bao L, Qin C. Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00979-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Suntronwong N, Yorsaeng R, Puenpa J, Auphimai C, Thongmee T, Vichaiwattana P, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Assawakosri S, Nilyanimit P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. Vaccines 2022;10:391. [DOI: 10.3390/vaccines10030391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 8 |
Giron CC, Laaksonen A, da Silva FLB. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies.. [DOI: 10.1101/2022.01.29.478316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Assawakosri S, Kanokudom S, Suntronwong N, Auphimai C, Nilyanimit P, Vichaiwattana P, Thongmee T, Duangchinda T, Chantima W, Pakchotanon P, Srimuan D, Thatsanatorn T, Klinfueng S, Yorsang R, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Honsawek S, Poovorawan Y. Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.. [DOI: 10.1101/2022.01.28.22269986] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
